Ubs Asset Management Americas Inc Cure Vac N.V. Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Cure Vac N.V. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 201,329 shares of CVAC stock, worth $1.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
201,329
Previous 279,656
28.01%
Holding current value
$1.1 Million
Previous $774,000
41.21%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding CVAC
# of Institutions
103Shares Held
14.2MCall Options Held
270KPut Options Held
114K-
Black Rock Inc. New York, NY2.25MShares$12.3 Million0.0% of portfolio
-
Alpine Associates Management Inc. Englewood Cliffs, NJ1.97MShares$10.8 Million0.58% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$8.58 Million10.6% of portfolio
-
Qube Research & Technologies LTD London, X01.18MShares$6.47 Million0.01% of portfolio
-
Water Island Capital LLC New York, NY957KShares$5.23 Million1.03% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $1.03B
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...